During the trial, insulin-induced hypoglycaemia (plasma glucose: <3 mM), in the absence of glibenclamide or dapagliflozin, produced a >700% increase in circulating glucagon in the control group, but only a 54% increase in participants with T1D. The gene discussed is GCG; the disease is type 1 diabetes mellitus.